Zentraxa announce seed financing to progress their platform technology for precision biomaterials
Science Angel Syndicate (SAS) are excited to announce their investment alongside Future Planet Capital and Bristol Private Equity Club (BPEC) into Zentraxa who are developing their innovative Zentide platform for engineering bespoke biomaterials.
With generous support of their recently awarded Innovate UK grant, Zentraxa is rapidly moving towards contracted commercial concept development in both medical adhesives and personal care. They are partnering with two leading multi-billion-pound corporations in these high-potential and lucrative markets. Zentraxa’s platform uses advanced scientific engineering to design precision peptide sequences with distinct functional properties that are commercially viable and can easily be integrated with existing systems. This could be in medicine, for example, skin bonding and wound care, or personal use, such as skin and hair.
This investment will further support product development and enable scale-up of their platform technology.
Dr Johnathan Matlock, Director and Co-founder of SAS, says “Biomanufacturing has emerged as a solution for developing biomaterials with unique properties that were previously inaccessible. Zentraxa has a platform technology that gives them an unfair advantage when producing biomaterials that will transform the performance of everyday products. We are delighted to have facilitated our investors to support Zentraxa in this funding round and support their Innovate UK grant.”
Jonathan Wogel, Executive Chair and Director of Zentraxa, says: “We are excited to develop our technology in line with the needs of our new commercial partners and deliver innovative material solutions to people as soon as possible. The funding will allow us to move quickly and hit our production milestones effectively.”
Zentraxa’s platform, Zentide, is particularly effective at producing materials that are difficult to make. With proof-of-concept projects in the pipeline, and commercial scale development lined up behind them, Zentraxa aims to lead the charge in producing scalable, sustainable by design, innovative biomaterials to improve performance in everyday products.
Hassan Mahmudul, Associate at UK Innovation & Science Seed Fund, Future Planet Capital, says: “We are delighted to support Zentraxa on their journey to build scalable, sustainable biomaterials for health, industrial and personal uses. There are meaningful and wide-ranging applications for the innovative biomaterials that Zentraxa are creating. We look forward to seeing how Zentraxa progresses in the coming months.”
*Risk disclaimer: Investment in early-stage companies involves risks such as illiquidity, lack of dividends, loss of investment and dilution. For professional investors only.
Public relations enquiries
Dr Johnathan Matlock, Director
johnathan@scienceangelsyndicate.com
About Science Angel Syndicate
Science Angel Syndicate was founded in 2021 with a mission to source world-class scientific discoveries, provide unique scientific due diligence and help our members to identify exceptional investment opportunities that tackle the most important global challenges. Our collective knowledge helps our members invest in the most exciting companies of tomorrow, founded by leading scientists at the forefront of their fields.
Learn more about Science Angel Syndicate: www.scienceangelsyndicate.com
Company Contact Zentraxa
Zentraxa
E: info@zentraxa.com
About Zentraxa
Zentraxa was founded in 2017 with a vision of precision engineering biomaterials for purpose. Starting as a spin-out from the University of Bristol, Zentraxa specialises in the design, production and testing of novel biomaterials. Their technology offers performance enhancing ingredients that are easily integrated into existing products and manufacturing lines. Zentraxa uses the versatility of natural systems to enhance product development pipelines and select and engineer desirable features, such as strong adhesion, stiffness or thermal stability, to create bespoke solutions.
For more information, please visit www.zentraxa.com.
